Reactive oxygen species (ROS) play a key role in the pathogenesis of cardiac remodeling and the subsequent progression to heart failure (HF). Nicotinamide adenosine dinucleotide phosphate (NADPH) oxidases (NOXs) are one of the major sources of ROS and are expressed in different heart cell types, including cardiomyocytes, endothelial cells, fibroblasts, and inflammatory cells.
Recent Advances:
NOX-derived ROS are usually produced in a regulated and spatially confined fashion and typically linked to specific signaling. The two main cardiac isoforms, namely nicotinamide adenine dinucleotide phosphate oxidase isoform 2 (NOX2) and nicotinamide adenine dinucleotide phosphate oxidase isoform 4 (NOX4), possess different biochemical and (patho)physiological properties and exert distinct effects on the cardiac phenotype in many settings. Recent work has defined important cell-specific effects of NOX2 that contribute to pathological cardiac remodeling and dysfunction. NOX4, on the other hand, may exert protective effects by stimulating adaptive stress responses, with recent data showing that NOX4-mediated signaling regulates transcription and metabolism in the heart.
Critical Issues:
The inhibition of NOX2 appears to be a very promising therapeutic target to ameliorate pathological cardiac remodeling. If the beneficial effects of NOX4 can be enhanced, this might be a unique approach to boosting adaptive responses and thereby impact cell survival, activation, contractility, and growth.
Future Directions:
Increasing knowledge regarding the intricacies of NOX-mediated signaling may yield tractable therapeutic targets, in contrast to the non-specific targeting of oxidative stress. Antioxid. Redox Signal. 38, 371–387.
Get full access to this article
View all access options for this article.
References
1.
AdamO, FrostG, CustodisF, et al.Role of Rac1 GTPase activation in atrial fibrillation. J Am Coll Cardiol, 2007; 50(4):359–367.
2.
AgoT, KurodaJ, PainJ, et al.Upregulation of Nox4 by hypertrophic stimuli promotes apoptosis and mitochondrial dysfunction in cardiac myocytes. Circ Res, 2010; 106(7):1253–1264.
3.
AkkiA, SmithK, SeymourA-ML. Compensated cardiac hypertrophy is characterised by a decline in palmitate oxidation. Mol Cell Biochem, 2008; 311(1):215–224.
4.
AnilkumarN, JoseGS, SawyerI, et al. A 28-kDa splice variant of NADPH oxidase-4 is nuclear-localized and involved in redox signaling invascular cells. Arterioscler Thromb Vasc Biol 2013;33(4):e104–-e112.
5.
AnratherJ, RacchumiG, IadecolaC. NF-κB regulates phagocytic NADPH oxidase by inducing the expression of gp91phox. J Biol Chem, 2006; 281(9):5657–5667.
6.
BánfiB, ClarkRA, StegerK, et al.Two novel proteins activate superoxide generation by the NADPH oxidase NOX1. J Biol Chem, 2003; 278(6):3510–3513.
7.
BánfiB, TironeF, DurusselI, et al.Mechanism of Ca2+ activation of the NADPH oxidase 5 (NOX5). J Biol Chem, 2004; 279(18):18583–18591.
8.
BargerPM, BrandtJM, LeoneTC, et al.Deactivation of peroxisome proliferator–activated receptor-α during cardiac hypertrophic growth. J Clin Invest, 2000; 105(12):1723–1730.
9.
BauersachsJ, GaluppoP, FraccarolloD, et al.Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation, 2001; 104(9):982–985.
10.
BeiL, LuY, EklundEA. HOXA9 activates transcription of the gene encoding gp91Phox during myeloid differentiation. J Biol Chem, 2005; 280(13):12359–12370.
11.
BellRM, CaveAC, JoharS, et al.Pivotal role of NOX-2-containing NADPH oxidase in early ischemic preconditioning. FASEB J, 2005; 19(14):2037–2039.
12.
BendallJK, CaveAC, HeymesC, et al.Pivotal role of a gp91phox-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation, 2002; 105(3):293–296.
13.
BerettaM, SantosCX, MolenaarC, et al.Nox4 regulates InsP3 receptor-dependent Ca2+ release into mitochondria to promote cell survival. EMBO J, 2020; 39(19):e103530.
14.
BonelloS, ZähringerC, BelAibaRS, et al.Reactive oxygen species activate the HIF-1α promoter via a functional NFκB site. Arterioscler Thromb Vasc Biol, 2007; 27(4):755–761.
15.
BrandesRP, WeissmannN, SchröderK. Nox family NADPH oxidases: Molecular mechanisms of activation. Free Radic Biol Med 2014; 76:208–226.
16.
BrandtM, DörschmannH, KhraisatS, et al.Telomere shortening in hypertensive heart disease depends on oxidative DNA damage and predicts impaired recovery of cardiac function in heart failure. Hypertension, 2022; 79(10):2173–2184.
17.
BrandtM, GarlapatiV, OelzeM, et al.NOX2 amplifies acetaldehyde-mediated cardiomyocyte mitochondrial dysfunction in alcoholic cardiomyopathy. Sci Rep, 2016; 6(1):1–16.
18.
BrewerAC, MurrayTV, ArnoM, et al.Nox4 regulates Nrf2 and glutathione redox in cardiomyocytes in vivo. Free Radic Biol Med, 2011; 51(1):205–215.
19.
BurchfieldJS, XieM, HillJA. Pathological ventricular remodeling: Mechanisms: Part 1 of 2. Circulation, 2013; 128(4):388–400.
20.
BurgoyneJR, Mongue-DinH, EatonP, et al.Redox signaling in cardiac physiology and pathology. Circ Res, 2012; 111(8):1091–1106.
21.
ByrneJA, GrieveDJ, BendallJK, et al.Contrasting roles of NADPH oxidase isoforms in pressure-overload versus angiotensin II–induced cardiac hypertrophy. Circ Res, 2003; 93(9):802–805.
22.
Cantu-MedellinN, KelleyEE. Xanthine oxidoreductase-catalyzed reactive species generation: A process in critical need of reevaluation. Redox Biol, 2013; 1(1):353–358.
23.
CarnicerR, CrabtreeMJ, SivakumaranV, et al.Nitric oxide synthases in heart failure. Antioxid Redox Signal, 2013; 18(9):1078–1099.
24.
CraigeSM, ChenK, PeiY, et al.NADPH oxidase 4 promotes endothelial angiogenesis through endothelial nitric oxide synthase activation. Circulation, 2011; 124(6):731–740.
25.
CucoranuI, ClempusR, DikalovaA, et al.NAD (P) H oxidase 4 mediates transforming growth factor-β1–induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res, 2005; 97(9):900–907.
26.
DieboldI, PetryA, HessJ, et al.The NADPH oxidase subunit NOX4 is a new target gene of the hypoxia-inducible factor-1. Mol Biol Cell, 2010; 21(12):2087–2096.
27.
DikalovS.Cross talk between mitochondria and NADPH oxidases. Free Radic Biol Med, 2011; 51(7):1289–1301.
28.
DinauerMC, PierceE, BrunsG, et al.Human neutrophil cytochrome b light chain (p22-phox). Gene structure, chromosomal location, and mutations in cytochrome-negative autosomal recessive chronic granulomatous disease. J Clin Invest, 1990; 86(5):1729–1737.
29.
DoerriesC, GroteK, Hilfiker-KleinerD, et al.Critical role of the NAD (P) H oxidase subunit p47 phox for left ventricular remodeling/dysfunction and survival after myocardial infarction. Circ Res, 2007; 100(6):894–903.
30.
DornGW.Apoptotic and non-apoptotic programmed cardiomyocyte death in ventricular remodelling. Cardiovasc Res, 2009; 81(3):465–473.
DrummondGR, SobeyCG. Endothelial NADPH oxidases: Which NOX to target in vascular disease?. Trends Endocrinol Metab, 2014; 25(9):452–463.
33.
DudleySCJr, HochNE, McCannLA, et al.Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: Role of the NADPH and xanthine oxidases. Circulation, 2005; 112(9):1266–1273.
34.
EklundEA, LuoW, SkalnikDG. Characterization of three promoter elements and cognate DNA binding protein (s) necessary for IFN-gamma induction of gp91-phox transcription. J Immunol, 1996; 157(6):2418–2429.
35.
EmmersonA, TrevelinSC, Mongue-DinH, et al.Nox2 in regulatory T cells promotes angiotensin II–induced cardiovascular remodeling. J Clin Invest, 2018; 128(7):3088–3101.
36.
EricksonJR, Mei-lingAJ, GuanX, et al.A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. Cell, 2008; 133(3):462–474.
37.
FinckBN, LehmanJJ, LeoneTC, et al.The cardiac phenotype induced by PPARα overexpression mimics that caused by diabetes mellitus. J Clin Invest, 2002; 109(1):121–130.
38.
ForresterSJ, KikuchiDS, HernandesMS, et al.Reactive oxygen species in metabolic and inflammatory signaling. Circ Res, 2018; 122(6):877–902.
39.
FreyN, KatusHA, OlsonEN, et al.Hypertrophy of the heart: A new therapeutic target?. Circulation, 2004; 109(13):1580–1589.
40.
FuY, ZhangY, WangZ, et al.Regulation of NADPH oxidase activity is associated with miRNA-25-mediated NOX4 expression in experimental diabetic nephropathy. Am J Nephrol, 2010; 32(6):581–589.
41.
GeisztM, LekstromK, WittaJ, et al.Proteins homologous to p47phox and p67phox support superoxide production by NAD (P) H oxidase 1 in colon epithelial cells. J Biol Chem, 2003; 278(22):20006–20012.
42.
GeraldD, BerraE, FrapartYM, et al.JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell, 2004; 118(6):781–794.
43.
GlembotskiCC.The role of the unfolded protein response in the heart. J Mol Cell Cardiol, 2008; 44(3):453–459.
44.
GraySP, Di MarcoE, KennedyK, et al.Reactive oxygen species can provide atheroprotection via NOX4-dependent inhibition of inflammation and vascular remodeling. Arterioscler Thromb Vasc Biol, 2016; 36(2):295–307.
45.
GrieveDJ, ByrneJA, SivaA, et al.Involvement of the nicotinamide adenosine dinucleotide phosphate oxidase isoform Nox2 in cardiac contractile dysfunction occurring in response to pressure overload. J Am Coll Cardiol, 2006; 47(4):817–826.
46.
GuzikTJ, ChenW, GongoraMC, et al.Calcium-dependent NOX5 nicotinamide adenine dinucleotide phosphate oxidase contributes to vascular oxidative stress in human coronary artery disease. J Am Coll Cardiol, 2008; 52(22):1803–1809.
47.
HafstadAD, HansenSS, LundJ, et al.NADPH oxidase 2 mediates myocardial oxygen wasting in obesity. Antioxidants, 2020; 9(2):171.
48.
HanJ, BackSH, HurJ, et al.ER-stress-induced transcriptional regulation increases protein synthesis leading to cell death. Nat Cell Biol, 2013; 15(5):481–490.
49.
HancockM, HafstadAD, NabeebaccusAA, et al.Myocardial NADPH oxidase-4 regulates the physiological response to acute exercise. Elife, 2018; 7:e41044.
50.
HansenSS, PedersenTM, MarinJ, et al.Overexpression of NOX2 exacerbates AngII-mediated cardiac dysfunction and metabolic remodelling. Antioxidants, 2022; 11(1):143.
51.
HarrisonCB, TrevelinSC, RichardsDA, et al.Fibroblast Nox2 (NADPH oxidase-2) regulates ANG II (angiotensin II)–induced vascular remodeling and hypertension via paracrine signaling to vascular smooth muscle cells. Arterioscler Thromb Vasc Biol, 2021; 41(2):698–710.
52.
HarveyAP, RobinsonE, EdgarKS, et al.Downregulation of PPARα during experimental left ventricular hypertrophy is critically dependent on Nox2 NADPH oxidase signalling. Int J Mol Sci, 2020; 21(12):4406.
53.
HeBJ, JoinerM-LA, SinghMV, et al.Oxidation of CaMKII determines the cardiotoxic effects of aldosterone. Nat Med, 2011; 17(12):1610–1618.
54.
HeckerL, LogsdonNJ, KurundkarD, et al.Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance. Sci Transl Med, 2014; 6(231):231ra247.
55.
HegyiB, BorstJM, BaileyLR, et al.Hyperglycemia regulates cardiac K+ channels via O-GlcNAc-CaMKII and NOX2-ROS-PKC pathways. Basic Res Cardiol, 2020; 115(6):1–19.
56.
HeymesC, BendallJK, RatajczakP, et al.Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol, 2003; 41(12):2164–2171.
57.
HiranoK, ChenWS, ChuengAL, et al.Discovery of GSK2795039, a novel small molecule NADPH oxidase 2 inhibitor. Antioxid Redox Signal, 2015; 23(5):358–374.
58.
HölscherM, SchäferK, KrullS, et al.Unfavourable consequences of chronic cardiac HIF-1α stabilization. Cardiovasc Res, 2012; 94(1):77–86.
59.
HustiZ, VarróA, BaczkóI. Arrhythmogenic remodeling in the failing heart. Cells, 2021; 10(11):3203.
60.
JacobsenBM, SkalnikDG. YY1 binds five cis-elements and trans-activates the myeloid cell-restricted gp91phox promoter. J Biol Chem, 1999; 274(42):29984–29993.
61.
JonesSA, O'DonnellVB, WoodJD, et al.Expression of phagocyte NADPH oxidase components in human endothelial cells. Am J Physiol, 1996; 271(4):H1626–H1634.
62.
KaludercicN, CarpiA, NagayamaT, et al.Monoamine oxidase B prompts mitochondrial and cardiac dysfunction in pressure overloaded hearts. Antioxid Redox Signal, 2014; 20(2):267–280.
63.
KaludercicN, TakimotoE, NagayamaT, et al.Monoamine oxidase A–mediated enhanced catabolism of norepinephrine contributes to adverse remodeling and pump failure in hearts with pressure overload. Circ Res, 2010; 106(1):193–202.
64.
KhodoSN, DizinE, SossauerG, et al.NADPH-oxidase 4 protects against kidney fibrosis during chronic renal injury. J Am Soc Nephrol, 2012; 23(12):1967–1976.
65.
KimYM, GuzikTJ, ZhangYH, et al.A myocardial Nox2 containing NAD (P) H oxidase contributes to oxidative stress in human atrial fibrillation. Circ Res, 2005; 97(7):629–636.
66.
KimYM, KattachH, RatnatungaC, et al.Association of atrial nicotinamide adenine dinucleotide phosphate oxidase activity with the development of atrial fibrillation after cardiac surgery. J Am Coll Cardiol, 2008; 51(1):68–74.
67.
KrijnenP, MeischlC, HackC, et al.Increased Nox2 expression in human cardiomyocytes after acute myocardial infarction. J Clin Pathol, 2003; 56(3):194–199.
68.
KurodaJ, AgoT, MatsushimaS, et al.NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart. Proc Natl Acad Sci U S A, 2010; 107(35):15565–15570.
69.
LangbeinH, BrunssenC, HofmannA, et al.NADPH oxidase 4 protects against development of endothelial dysfunction and atherosclerosis in LDL receptor deficient mice. Eur Heart J, 2016; 37(22):1753–1761.
70.
LassègueB, GriendlingKK. NADPH oxidases: Functions and pathologies in the vasculature. Arterioscler Thromb Vasc Biol, 2010; 30(4):653–661.
71.
LassègueB, San MartínA, GriendlingKK. Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system. Circ Res, 2012; 110(10):1364–1390.
72.
LassègueB, SorescuD, SzöcsK, et al.Novel gp91 phox homologues in vascular smooth muscle cells: Nox1 mediates angiotensin II–induced superoxide formation and redox-sensitive signaling pathways. Circ Res, 2001; 88(9):888–894.
73.
LiJ, IchikawaT, VillacortaL, et al.Nrf2 protects against maladaptive cardiac responses to hemodynamic stress. Arterioscler Thromb Vasc Biol, 2009; 29(11):1843–1850.
74.
LiY, MoucheS, SajicT, et al.Deficiency in the NADPH oxidase 4 predisposes towards diet-induced obesity. Int J Obes, 2012; 36(12):1503–1513.
75.
LooiYH, GrieveDJ, SivaA, et al.Involvement of Nox2 NADPH oxidase in adverse cardiac remodeling after myocardial infarction. Hypertension, 2008; 51(2):319–325.
76.
LopaschukGD, KarwiQG, TianR, et al.Cardiac energy metabolism in heart failure. Circ Res, 2021; 128(10):1487–1513.
77.
LuS, LiaoZ, LuX, et al.Hyperglycemia acutely increases cytosolic reactive oxygen species via O-linked GlcNAcylation and CaMKII activation in mouse ventricular myocytes. Circ Res, 2020; 126(10):e80–e96.
78.
LuX, MurphyTC, NanesMS, et al.PPARγ regulates hypoxia-induced Nox4 expression in human pulmonary artery smooth muscle cells through NF-κB. Am J Physiol Lung Cell Mol Physiol, 2010; 299(4):L559–L566.
79.
LyleAN, DeshpandeNN, TaniyamaY, et al.Poldip2, a novel regulator of Nox4 and cytoskeletal integrity in vascular smooth muscle cells. Circ Res, 2009; 105(3):249–259.
80.
MaJ, WangY, ZhengD, et al.Rac1 signalling mediates doxorubicin-induced cardiotoxicity through both reactive oxygen species-dependent and-independent pathways. Cardiovasc Res, 2013; 97(1):77–87.
81.
MailletM, Van BerloJH, MolkentinJD. Molecular basis of physiological heart growth: Fundamental concepts and new players. Nat Rev Mol Cell Biol, 2013; 14(1):38–48.
82.
MatsunoK, IwataK, MatsumotoM, et al.NOX1/NADPH oxidase is involved in endotoxin-induced cardiomyocyte apoptosis. Free Radic Biol Med, 2012; 53(9):1718–1728.
83.
MatsushimaS, KurodaJ, AgoT, et al.Broad suppression of NADPH oxidase activity exacerbates ischemia/reperfusion injury through inadvertent downregulation of hypoxia-inducible factor-1α and upregulation of peroxisome proliferator–activated receptor-α. Circ Res, 2013a;112(8):1135–1149.
84.
MatsushimaS, KurodaJ, AgoT, et al.Increased oxidative stress in the nucleus caused by Nox4 mediates oxidation of HDAC4 and cardiac hypertrophy. Circ Res, 2013b;112(4):651–663.
85.
MatsushimaS, KurodaJ, ZhaiP, et al.Tyrosine kinase FYN negatively regulates NOX4 in cardiac remodeling. J Clin Invest, 2016; 126(9):3403–3416.
86.
MighiuAS, RecaldeA, ZibernaK, et al.Inducibility, but not stability, of atrial fibrillation is increased by NOX2 overexpression in mice. Cardiovasc Res, 2021; 117(11):2354–2364.
87.
MirS, GoldenBDO, GriessBJ, et al.Upregulation of Nox4 induces a pro-survival Nrf2 response in cancer-associated fibroblasts that promotes tumorigenesis and metastasis, in part via Birc5 induction. Breast Cancer Res, 2022; 24(1):1–19.
88.
MistryRK, MurrayTV, PrysyazhnaO, et al.Transcriptional regulation of cystathionine-γ-lyase in endothelial cells by NADPH oxidase 4-dependent signaling. J Biol Chem, 2016; 291(4):1774–1788.
MontezanoAC, BurgerD, ParaviciniTM, et al.Nicotinamide adenine dinucleotide phosphate reduced oxidase 5 (Nox5) regulation by angiotensin II and endothelin-1 is mediated via calcium/calmodulin-dependent, rac-1-independent pathways in human endothelial cells. Circ Res, 2010; 106(8):1363–1373.
91.
MoonJ-S, NakahiraK, ChungK-P, et al.NOX4-dependent fatty acid oxidation promotes NLRP3 inflammasome activation in macrophages. Nat Med, 2016; 22(9):1002–1012.
92.
MurdochCE, ChaubeyS, ZengL, et al.Endothelial NADPH oxidase-2 promotes interstitial cardiac fibrosis and diastolic dysfunction through proinflammatory effects and endothelial-mesenchymal transition. J Am Coll Cardiol, 2014; 63(24):2734–2741.
93.
MurdochCE, ZhangM, CaveAC, et al.NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure. Cardiovasc Res, 2006; 71(2):208–215.
94.
NabeebaccusAA, ReumillerCM, ShenJ, et al.The regulation of cardiac intermediary metabolism by NADPH oxidases. Cardiovasc Res, 2022; 118(17):3305–3319.
95.
NabeebaccusAA, ZoccaratoA, HafstadAD, et al.Nox4 reprograms cardiac substrate metabolism via protein O-GlcNAcylation to enhance stress adaptation. JCI Insight, 2017; 2(24):e96184.
96.
NakamuraM, SadoshimaJ. Mechanisms of physiological and pathological cardiac hypertrophy. Nat Rev Cardiol, 2018; 15(7):387–407.
97.
NauseefWM. The phagocyte NOX2 NADPH oxidase in microbial killing and cell signaling. Curr Opin Immunol 2019; 60:130–140.
98.
NedianiC, BorchiE, GiordanoC, et al.NADPH oxidase-dependent redox signaling in human heart failure: Relationship between the left and right ventricle. J Mol Cell Cardiol, 2007; 42(4):826–834.
99.
NickelAG, Von HardenbergA, HohlM, et al.Reversal of mitochondrial transhydrogenase causes oxidative stress in heart failure. Cell Metab, 2015; 22(3):472–484.
100.
Nlandu-KhodoS, DissardR, HaslerU, et al.NADPH oxidase 4 deficiency increases tubular cell death during acute ischemic reperfusion injury. Sci Rep, 2016; 6(1):1–14.
101.
OakleyFD, AbbottD, LiQ, et al.Signaling components of redox active endosomes: The redoxosomes. Antioxid Redox Signal, 2009; 11(6):1313–1333.
PaolocciN, BiondiR, BettiniM, et al.Oxygen radical-mediated reduction in basal and agonist-evoked NO release in isolated rat heart. J Mol Cell Cardiol, 2001; 33(4):671–679.
104.
PatelVB, WangZ, FanD, et al.Loss of p47phox subunit enhances susceptibility to biomechanical stress and heart failure because of dysregulation of cortactin and actin filaments. Circ Res, 2013; 112(12):1542–1556.
105.
PendyalaS, MoitraJ, KalariS, et al.Nrf2 regulates hyperoxia-induced Nox4 expression in human lung endothelium: Identification of functional antioxidant response elements on the Nox4 promoter. Free Radic Biol Med, 2011; 50(12):1749–1759.
QinF, SimeoneM, PatelR. Inhibition of NADPH oxidase reduces myocardial oxidative stress and apoptosis and improves cardiac function in heart failure after myocardial infarction. Free Radic Biol Med, 2007; 43(2):271–281.
108.
QuinlanCL, GoncalvesRL, Hey-MogensenM, et al.The 2-oxoacid dehydrogenase complexes in mitochondria can produce superoxide/hydrogen peroxide at much higher rates than complex I. J Biol Chem, 2014; 289(12):8312–8325.
109.
ReillySN, LiuX, CarnicerR, et al.Up-regulation of miR-31 in human atrial fibrillation begets the arrhythmia by depleting dystrophin and neuronal nitric oxide synthase. Sci Transl Med, 2016; 8(340):340ra374.
110.
SagCM, SchnelleM, ZhangJ, et al.Distinct regulatory effects of myeloid cell and endothelial cell NAPDH oxidase 2 on blood pressure. Circulation, 2017; 135(22):2163–2177.
111.
SanoM, MinaminoT, TokoH, et al.p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature, 2007; 446(7134):444–448.
112.
SantosCX, HafstadAD, BerettaM, et al.Targeted redox inhibition of protein phosphatase 1 by Nox4 regulates eIF 2α-mediated stress signaling. EMBO J, 2016; 35(3):319–334.
113.
SatohM, OgitaH, TakeshitaK, et al.Requirement of Rac1 in the development of cardiac hypertrophy. Proc Natl Acad Sci U S A, 2006; 103(19):7432–7437.
114.
SchnelleM, SawyerI, AnilkumarN, et al.NADPH oxidase-4 promotes eccentric cardiac hypertrophy in response to volume overload. Cardiovasc Res, 2021; 117(1):178–187.
115.
SchröderK, ZhangM, BenkhoffS, et al.Nox4 is a protective reactive oxygen species generating vascular NADPH oxidase. Circ Res, 2012; 110(9):1217–1225.
116.
SchroederMA, LauAZ, ChenAP, et al.Hyperpolarized 13C magnetic resonance reveals early-and late-onset changes to in vivo pyruvate metabolism in the failing heart. Eur J Heart Fail, 2013; 15(2):130–140.
117.
SchürmannC, RezendeF, KruseC, et al.The NADPH oxidase Nox4 has anti-atherosclerotic functions. Eur Heart J, 2015; 36(48):3447–3456.
118.
SchwemmleinJ, MaackC, BerteroE. Mitochondria as therapeutic targets in heart failure. Curr Heart Fail Rep, 2022; 19(2):27–37.
119.
SciarrettaS, ZhaiP, ShaoD, et al.Activation of NADPH oxidase 4 in the endoplasmic reticulum promotes cardiomyocyte autophagy and survival during energy stress through the protein kinase RNA-activated-like endoplasmic reticulum kinase/eukaryotic initiation factor 2α/activating transcription factor 4 pathway. Circ Res, 2013; 113(11):1253–1264.
120.
SegalAW, JonesOT. Novel cytochrome b system in phagocytic vacuoles of human granulocytes. Nature, 1978; 276(5687):515–517.
121.
SemenzaGL.Life with oxygen. Science, 2007; 318(5847):62–64.
122.
ShanmugamG, ChallaAK, LitovskySH, et al.Enhanced Keap1-Nrf2 signaling protects the myocardium from isoproterenol-induced pathological remodeling in mice. Redox Biol, 2019; 27:101212.
123.
ShenE, LiY, LiY, et al.Rac1 is required for cardiomyocyte apoptosis during hyperglycemia. Diabetes, 2009; 58(10):2386–2395.
124.
SirkerA, MurdochCE, ProttiA, et al. Cell-specific effects of Nox2 on the acute and chronic response to myocardial infarction. J Mol Cell Cardiol 2016; 98:11–17.
125.
SkalnikD, StraussE, OrkinS. CCAAT displacement protein as a repressor of the myelomonocytic-specific gp91-phox gene promoter. J Biol Chem, 1991; 266(25):16736–16744.
126.
SmyrniasI, ZhangX, ZhangM, et al.Nicotinamide adenine dinucleotide phosphate oxidase-4–dependent upregulation of nuclear factor erythroid–derived 2-like 2 protects the heart during chronic pressure overload. Hypertension, 2015; 65(3):547–553.
127.
SomasuntharamI, BoopathyAV, KhanRS, et al.Delivery of Nox2-NADPH oxidase siRNA with polyketal nanoparticles for improving cardiac function following myocardial infarction. Biomaterials, 2013; 34(31):7790–7798.
128.
SorescuD, WeissD, LassègueB, et al.Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation, 2002; 105(12):1429–1435.
129.
StromJ, ChenQM. Loss of Nrf2 promotes rapid progression to heart failure following myocardial infarction. Toxicol Appl Pharmacol 2017; 327:52–58.
130.
SturrockA, CahillB, NormanK, et al.Transforming growth factor-β1 induces Nox4 NAD (P) H oxidase and reactive oxygen species-dependent proliferation in human pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol, 2006; 290(4):L661–L673.
131.
SunJ, ChenW, LiS, et al.Nox4 promotes RANKL-induced autophagy and osteoclastogenesis via activating ROS/PERK/eIF-2α/ATF4 pathway. Front Pharmacol, 2021; 12:751845.
132.
SuzukiS, KumatoriA, HaagenI-A, et al.PU. 1 as an essential activator for the expression of gp91phox gene in human peripheral neutrophils, monocytes, and B lymphocytes. Proc Natl Acad Sci U S A, 1998; 95(11):6085–6090.
133.
TakeyaR, UenoN, KamiK, et al.Novel human homologues of p47phox and p67phox participate in activation of superoxide-producing NADPH oxidases. J Biol Chem, 2003; 278(27):25234–25246.
134.
TouyzRM, ChenX, TabetF, et al.Expression of a functionally active gp91phox-containing neutrophil-type NAD (P) H oxidase in smooth muscle cells from human resistance arteries: Regulation by angiotensin II. Circ Res, 2002; 90(11):1205–1213.
135.
TranDH, WangZV. Glucose metabolism in cardiac hypertrophy and heart failure. J Am Heart Assoc, 2019; 8(12):e012673.
136.
TrevelinSC, ZampetakiA, SawyerG, et al.Nox2-deficient Tregs improve heart transplant outcomes via their increased graft recruitment and enhanced potency. JCI Insight, 2021; 6(18):e149301.
137.
van der PolA, van GilstWH, VoorsAA, et al.Treating oxidative stress in heart failure: Past, present and future. Eur J Heart Fail, 2019; 21(4):425–435.
138.
VargaZV, KupaiK, SzűcsG, et al. MicroRNA-25-dependent up-regulation of NADPH oxidase 4 (NOX4) mediates hypercholesterolemia-induced oxidative/nitrative stress and subsequent dysfunction in the heart. J Mol Cell Cardiol 2013; 62:111–121.
139.
VattemKM, WekRC. Reinitiation involving upstream ORFs regulates ATF4 mRNA translation in mammalian cells. Proc Natl Acad Sci U S A, 2004; 101(31):11269–11274.
140.
VendrovAE, VendrovKC, SmithA, et al.NOX4 NADPH oxidase-dependent mitochondrial oxidative stress in aging-associated cardiovascular disease. Antioxid Redox Signal, 2015; 23(18):1389–1409.
141.
VermotA, Petit-HärtleinI, SmithSM, et al.NADPH oxidases (NOX): An overview from discovery, molecular mechanisms to physiology and pathology. Antioxidants, 2021; 10(6):890.
142.
VooKS, SkalnikDG. Elf-1 and PU.1 induce expression of gp91 phox via a promoter element mutated in a subset of chronic granulomatous disease patients. Blood, 1999; 93(10):3512–3520.
143.
WagnerS, DantzC, FlebbeH, et al. NADPH oxidase 2 mediates angiotensin II-dependent cellular arrhythmias via PKA and CaMKII. J Mol Cell Cardiol 2014; 75:206–215.
144.
WandersRJ, WaterhamHR, FerdinandusseS. Metabolic interplay between peroxisomes and other subcellular organelles including mitochondria and the endoplasmic reticulum. Front Cell Dev Biol, 2016; 3:83.
145.
WeiH, BedjaD, KoitabashiN, et al.Endothelial expression of hypoxia-inducible factor 1 protects the murine heart and aorta from pressure overload by suppression of TGF-β signaling. Proc Natl Acad Sci U S A, 2012; 109(14):E841–E850.
146.
WortelIM, van der MeerLT, KilbergMS, et al.Surviving stress: Modulation of ATF4-mediated stress responses in normal and malignant cells. Trends Endocrinol Metab, 2017; 28(11):794–806.
147.
XieM, BurchfieldJS, HillJA. Pathological ventricular remodeling: Therapies: Part 2 of 2. Circulation, 2013; 128(9):1021–1030.
148.
YangJ, BrownME, ZhangH, et al.High-throughput screening identifies microRNAs that target Nox2 and improve function after acute myocardial infarction. Am J Physiol Heart Circ Physiol, 2017; 312(5):H1002–H1012.
149.
YooS, PfennigerA, HoffmanJ, et al.Attenuation of oxidative injury with targeted expression of NADPH oxidase 2 short hairpin RNA prevents onset and maintenance of electrical remodeling in the canine atrium: A novel gene therapy approach to atrial fibrillation. Circulation, 2020; 142(13):1261–1278.
150.
YounS-W, LiY, KimY-M, et al.Modification of cardiac progenitor cell-derived exosomes by miR-322 provides protection against myocardial infarction through nox2-dependent angiogenesis. Antioxidants, 2019; 8(1):18.
151.
ZhabyeyevP, GandhiM, MoriJ, et al.Pressure-overload-induced heart failure induces a selective reduction in glucose oxidation at physiological afterload. Cardiovasc Res, 2013; 97(4):676–685.
152.
ZhangL, SheppardOR, ShahAM, et al.Positive regulation of the NADPH oxidase NOX4 promoter in vascular smooth muscle cells by E2F. Free Radic Biol Med, 2008; 45(5):679–685.
153.
ZhangM, BrewerAC, SchröderK, et al.NADPH oxidase-4 mediates protection against chronic load-induced stress in mouse hearts by enhancing angiogenesis. Proc Natl Acad Sci U S A, 2010; 107(42):18121–18126.
154.
ZhangM, Mongue-DinH, MartinD, et al.Both cardiomyocyte and endothelial cell Nox4 mediate protection against hemodynamic overload-induced remodelling. Cardiovasc Res, 2018; 114(3):401–408.
155.
ZhangM, ProsserBL, BamboyeMA, et al.Contractile function during angiotensin-II activation: Increased Nox2 activity modulates cardiac calcium handling via phospholamban phosphorylation. J Am Coll Cardiol, 2015; 66(3):261–272.
156.
ZhangY, QiY, LiJ-J, et al.Stretch-induced sarcoplasmic reticulum calcium leak is causatively associated with atrial fibrillation in pressure-overloaded hearts. Cardiovasc Res, 2021; 117(4):1091–1102.
157.
ZhaoQD, ViswanadhapalliS, WilliamsP, et al.NADPH oxidase 4 induces cardiac fibrosis and hypertrophy through activating Akt/mTOR and NFκB signaling pathways. Circulation, 2015; 131(7):643–655.
158.
ZhouB, TianR. Mitochondrial dysfunction in pathophysiology of heart failure. J Clin Invest, 2018; 128(9):3716–3726.
